+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

CEL-SCI Corp (CVM) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 44 Pages
  • April 2023
  • GlobalData
  • ID: 1291548
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

CEL-SCI Corp (CVM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

CEL-SCI Corp (CEL-SCI) is a biotechnology company that carries out the research and development of new immunotherapy products for the treatment of various cancer, autoimmune, and infectious diseases. Its core capabilities include drug discovery, research, development and manufacture of compound biological substances. CEL-SCI’s lead candidate Multikine (leukocyte interleukin), is an investigational immunotherapy against cancer and human papilloma virus (HPV). The company is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 in hospitalized patients and vaccines, CEL-2000 and CEL-4000 for rheumatoid arthritis using Ligand Epitope Antigen Presentation System (LEAPS) technology platform. CEL-SCI is headquartered in Fairfax, Virginia, the US.

CEL-SCI Corp Key Recent Developments

  • Dec 28, 2022: CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments
  • Aug 15, 2022: CEL-SCI reports third quarter fiscal 2022 financial results
  • Aug 08, 2022: CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors
  • Jun 08, 2022: CEL-SCI Corp to Present at LD Micro Invitational

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • CEL-SCI Corp - Key Facts
  • CEL-SCI Corp - Key Employees
  • CEL-SCI Corp - Key Employee Biographies
  • CEL-SCI Corp - Major Products and Services
  • CEL-SCI Corp - History
  • CEL-SCI Corp - Company Statement
  • CEL-SCI Corp - Locations And Subsidiaries
  • Head Office
Section 2 - Company Analysis
  • Company Overview
  • CEL-SCI Corp - Business Description
  • CEL-SCI Corp - Corporate Strategy
  • CEL-SCI Corp - SWOT Analysis
  • SWOT Analysis - Overview
  • CEL-SCI Corp - Strengths
  • CEL-SCI Corp - Weaknesses
  • CEL-SCI Corp - Opportunities
  • CEL-SCI Corp - Threats
  • CEL-SCI Corp - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • CEL-SCI Corp, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Dec 28, 2022: CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments
  • Aug 15, 2022: CEL-SCI reports third quarter fiscal 2022 financial results
  • Aug 08, 2022: CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors
  • Jun 08, 2022: CEL-SCI Corp to Present at LD Micro Invitational
  • May 16, 2022: CEL-SCI Reports Second Quarter Fiscal 2022 Financial Results
  • Feb 14, 2022: CEL-SCI Reports First Quarter Fiscal 2022 Financial Results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • CEL-SCI Corp, Key Facts
  • CEL-SCI Corp, Key Employees
  • CEL-SCI Corp, Key Employee Biographies
  • CEL-SCI Corp, Major Products and Services
  • CEL-SCI Corp, History
  • CEL-SCI Corp, Key Competitors
  • CEL-SCI Corp, Ratios based on current share price
  • CEL-SCI Corp, Annual Ratios
  • CEL-SCI Corp, Interim Ratios
  • CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • CEL-SCI Corp, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • CEL-SCI Corp, Performance Chart (2018 - 2022)
  • CEL-SCI Corp, Ratio Charts
  • CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Bioqual Inc
  • ImmunoGen Inc
  • Biopolymer Innovations Llc
  • Lentigen Technology Inc
  • Chinook Therapeutics Inc